GET DAILY SIGNALSCardlytics (CDLX) Q3 2026 Earnings: Revenue Declines 30% as Bank Changes Weigh on Results
Key Takeaways
- Cardlytics reported third quarter 2026 revenue of $32.9 million, down 30% year over year and below the consensus estimate of roughly $37 million.
- Billings, the gross amount billed to advertisers, fell 32% year over year to $57.2 million, reflecting tighter advertiser budgets and earlier bank-partner changes.
- Adjusted EBITDA stayed positive at $0.4 million, down from $3.3 million in the same quarter a year earlier.
- Adjusted Contribution as a percentage of revenue expanded to 59% from 54.4%, pointing to improved efficiency on a smaller revenue base.
- Monthly Active Users were 187 million, down from 230 million a year ago but up 1.2 million from the end of the second quarter.
- Fourth quarter guidance signals a return to sequential growth, with billings expected between $63 million and $69 million.
Earnings Context and Why It Matters
Cardlytics operates a purchase intelligence platform that converts card-transaction data into card-linked offers for advertisers and rewards for consumers. Its quarterly results matter because they shed light on both advertiser demand for digital marketing and the health of its bank-partner network. The company has been rebuilding after divesting its Bridg business in early 2026 and after changes in bank-partner relationships, including the loss of a major banking partner. Those shifts created difficult year-over-year comparisons that are expected to persist until early 2027. Investors are watching whether disciplined cost control and stabilizing supply can offset a softer revenue environment and move the business toward self-sustaining free cash flow. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026, ended September 30, 2026, Cardlytics reported revenue of $32.9 million, a 30% decline from the prior year and below the consensus estimate of approximately $37 million. Billings came in at $57.2 million, down 32% year over year. Adjusted Contribution was $19.4 million, down 24%, but improved to 59% of revenue from 54.4% a year earlier.
Adjusted EBITDA was positive at $0.4 million, compared with $3.3 million in the third quarter of 2025. Adjusted operating expenses declined 14% to $19 million, helped by workforce reductions and cloud-optimization efforts. Free cash flow was negative $1.6 million, an improvement from negative $2.7 million a year earlier. The company ended the quarter with $29.9 million in cash and cash equivalents and about $10.4 million available on its credit facility. On an adjusted basis, the net loss per share came in narrower than the consensus estimate of roughly $2.02 per share.
For the fourth quarter of 2026, Cardlytics guided to billings of $63 million to $69 million, revenue of $35 million to $39 million, Adjusted Contribution of $20 million to $23 million, and Adjusted EBITDA between negative $1 million and positive $2 million.
Market Reaction and Investor Sentiment
Cardlytics shares have been under significant pressure, with the stock down sharply over both the past three months and the trailing twelve-month period. The third quarter delivered a mixed picture: the adjusted loss per share beat expectations, but revenue fell short of consensus and fourth quarter revenue guidance also came in below analyst projections. Chief Executive Officer Amit Gupta acknowledged that third quarter results "came in below expectations," while pointing to progress in adding supply partners and growing the advertising base. That combination of a narrower-than-expected loss, weaker top-line performance, and cautious near-term guidance is likely to keep investor sentiment balanced between optimism about cost discipline and concern about the pace of the revenue recovery.
Forward Outlook and Key Factors to Monitor
The most important near-term signal is whether Cardlytics delivers the sequential growth embedded in its fourth quarter guidance. Management expects billings to rise 10% to 20% quarter over quarter, which would mark a return to sequential growth after a softer third quarter. Investors should watch whether this rebound actually materializes and whether it carries into 2027.
Balance sheet and liquidity remain central themes. With $29.9 million in cash and about $10.4 million available on its credit facility, the company has said it is "actively evaluating any and all options" to strengthen its balance sheet and cash flow. Any financing or strategic action could become a meaningful catalyst in the months ahead.
Finally, the bank-partner changes that created tough year-over-year comparisons are expected to anniversary in the first quarter of 2027. Until then, investors will likely focus on the trajectory of Monthly Active Users, the stability of the Adjusted Contribution margin, and whether cost reductions continue to narrow the gap between free cash flow and Adjusted EBITDA. Broader advertiser-budget trends will also remain a key external factor shaping demand. From what I see, monitoring these elements closely will be key to assessing the recovery path.
Using AI Tools in My Research Process
In my own analysis of names like Cardlytics, I often turn to Tickeron’s AI Screener to quickly filter for patterns and compare performance across peers. It helps surface relevant data points without spending hours on manual screens, which keeps my process efficient when evaluating quarterly updates and sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CDLX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CDLX turned positive on October 23, 2026. Looking at past instances where CDLX's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CDLX's RSI Oscillator exited the oversold zone, 40 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CDLX as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +5.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDLX advanced for three days, in 203 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CDLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CDLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.806) is normal, around the industry mean (-0.306). P/E Ratio (-0.118) is within average values for comparable stocks, (19.327). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.501). Dividend Yield (0.000) settles around the average of (0.077) among similar stocks. P/S Ratio (0.114) is also within normal values, averaging (1.860).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CDLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology that enables online banking, mobile banking and card-linked marketing
Industry AdvertisingMarketingServices
Advertisement